Suchergebnisse für pharmaceutical companies

Innovation in Pharmaceutical Mergers: Looking for a Miracle Cure?

The European Commission’s approach to analysing the negative effects of a merger on competition has recently changed. Whereas for years, competition authorities have mainly focused on the effects of a merger on prices, the impact on output, or the creation or strengthening of a dominant position in a given market, they are now examining the effects of a merger on innovation. The analysis of the…

Die Praxis des Jahres 2021 im Übernahmerecht

Dieser Beitrag bespricht die Praxis der Übernahmekommission (UEK) des Jahres 2021. Die UEK erliess dabei im Rahmen von 14 Verfahren insgesamt 16 Ver­fügungen.

Salärgovernance und neues Aktienrecht

In determining the compensation of directors and top management, the board of directors of public companies is faced with a structural conflict of interest. The aim to mitigate this conflict through an appropriate design of the procedure forms the essence of the say-on-pay rules introduced by the Swiss electorate in a public vote in 2013 and implemented on a transitional basis in the Ordinance…

Recent developments in Swiss competition law

Over the past few months the Courts issued quite a significant number of judgments. Generally, they favoured a strict competition policy in dealing with substantive law issues. However, this was not done to the detriment of the protection of the parties’ procedural rights...

Swiss Multinational Enterprises and Transnational Corruption: Management Matters

In 2016, the Office of the Attorney General of Switzerland sanctioned a Swiss corporation for having bribed a Libyan Minister. The same year, it opened a criminal proceeding against the Swiss bank BSI for its involvement in the corruption scandals surrounding the Malaysian company 1MDB. Swiss corporations are also currently under investigation in the Brazilian Petrobras scandal. At the…

Développements du droit suisse des OPA

This survey of Swiss takeover law focuses on some of the most interesting recent transactions, which are discussed under three aspects : material and territorial scope of the law ; companies which have opted out of mandatory offer for shareholders who pass the 33⅓ % threshold ; and share buy back programs. We also discuss the controversial issue whether a bidder may subject its offer to a…